Interim Financial Results to be Announced 24 November 2022

GENERAL

Fri, Nov 11 2022 08:30 am

INTERIM FINANCIAL RESULT TO BE ANNOUNCED 24 NOVEMBER 2022

Cancer diagnostics company Pacific Edge Limited (NZX:PEB) advises that its half year results for the six months ending 30 September 2022 will be released on Thursday 24 November 2022, prior to 10am.

This will be followed by an Investor and Analyst conference call at 11.00am (NZST). This investor briefing will be available via webcast (presentation slides and audio only) or ‘audio only’ service. Please follow the instructions outlined below to access the event.

Webcast Instructions
To join the investor briefing online, click on the link below to view, listen to and ask written questions on the Investor presentation directly from your laptop, tablet or mobile device. Audio will stream through your selected device, so be sure to have headphones or your volume turned up. If you have technical difficulties, please click the “Listen by Phone” button on the webcast player and dial the number provided.

To attend the webcast, please register at the following link:
https://event.webcasts.com/starthere.jsp?ei=1582035&tp_key=620c356fc9

Questions
Questions can be submitted online in writing via the Webcast platform or verbally via the audio call system when prompted.

The webcast will be available at the above link for 12 months following the event.

If you have any queries regarding the results announcement or the conference call, please contact Stacey Stanley on 03 479 5807 or [email protected].

ENDS

Approved for release by:

Pete Meintjes
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the test online.